Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Stockholders' Equity (Details Textual)

v3.23.3
Note 8 - Stockholders' Equity (Details Textual) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 08, 2023
Feb. 03, 2023
Jan. 30, 2023
Jan. 27, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         1,685,000,000 0        
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount         $ 1,200,000          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)         $ 1.55   $ 3.3 $ 1.55 $ 1.32  
Common Stock, Par or Stated Value Per Share (in dollars per share)         $ 0.0001   $ 0.0001      
Proceeds from Issuance of Private Placement $ 550,000       $ 550,000 $ 0        
Invagen Pharmaceuticals Inc [Member]                    
Contingent Fee, Percentage of Proceeds of Future Financings   7.50%                
Contingent Fee, Maximum Allowable Amount   $ 4,000,000                
Payment of Contingent Fee   $ 200,000                
Prefunded Warrant [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)       1,492,299            
Class of Warrants or Rights, Price Less Than Stock Issuance Price (in dollars per share)       $ 0.001            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 0.001            
January 2023 Warrants [Member]                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)       1,940,299            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 1.55            
Proceeds from Issuance or Sale of Equity       $ 240,000            
Class of Warrants or Rights, Offering Price (in dollars per share)       $ 0.125            
Warrants and Rights Outstanding, Term (Year)       3 years            
Securities Purchase Agreement [Member]                    
Stock Issued During Period, Shares, New Issues (in shares)       448,000            
Shares Issued, Price Per Share (in dollars per share)       $ 1.55            
Proceeds from Issuance or Sale of Equity       $ 3,000,000            
Private Placement [Member]                    
Sale of Stock, Number of Shares Issued in Transaction (in shares) 767,085                  
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.0001                  
Sale of Stock, Consideration Received on Transaction $ 550,000                  
Sale of Stock, Price Per Share (in dollars per share) $ 0.717                  
Share-Based Payment Arrangement, Option [Member]                    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         1 year 9 months 18 days          
Restricted Stock Units (RSUs) [Member]                    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         1 year 7 months 6 days          
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount         $ 100,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)             3,333      
Two Thousand Fifteen Incentive Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)     5,266,666             266,666
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)     10 years              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)               3,352,489